image
Innate Pharma S.A. IPHA
Healthcare - Biotechnology - NASDAQ - FR
Watchlist
$ 1.82
1.37 %
$ 168 M
Market Cap
-2.6
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one IPHA stock under the worst case scenario is HIDDEN Compared to the current market price of 1.82 USD, Innate Pharma S.A. is HIDDEN

IPHA Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one IPHA stock under the base case scenario is HIDDEN Compared to the current market price of 1.82 USD, Innate Pharma S.A. is HIDDEN

IPHA Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one IPHA stock under the best case scenario is HIDDEN Compared to the current market price of 1.82 USD, Innate Pharma S.A. is HIDDEN

IPHA Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart IPHA

image
1M -14.0%
6M -3%
1Y -19%
3Y -53%
5Y -234%
All
$2.6$2.6$2.5$2.5$2.4$2.4$2.3$2.3$2.2$2.2$2.1$2.1$2.0$2.0$1.9$1.9$1.8$1.8$1.7$1.7$1.6$1.615 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
12.6 M REVENUE
-75.68%
Growth Rates
1Year -75.68%
3Years 1.38%
5Years -28.80%
7Years -12.69%
10Years 30.12%
-51.6 M OPERATING INCOME
-307.10%
Growth Rates
1Year -307.10%
3Years -2.55%
5Years -13.77%
7Years -3.70%
10Years -9.95%
-49.5 M NET INCOME
-553.51%
Growth Rates
1Year -553.51%
3Years 2.15%
5Years -18.97%
7Years -0.32%
10Years -9.67%
-6.9 M OPERATING CASH FLOW
78.82%
Growth Rates
1Year 78.82%
3Years 50.96%
5Years -3.67%
7Years 24.22%
10Years 9.22%
9.2 M INVESTING CASH FLOW
-55.41%
Growth Rates
1Year -55.41%
3Years 129.15%
5Years 16.52%
7Years 12.72%
10Years 15.99%
-6.01 M FINANCING CASH FLOW
-205.60%
Growth Rates
1Year -205.60%
3Years -6.97%
5Years -1.50%
7Years -33.52%
10Years -1.19%
276 K REVENUE
-97.76%
Growth Rates
1Year -75.68%
3Years 1.38%
5Years -28.80%
7Years -12.69%
10Years 30.12%
-25.3 M OPERATING INCOME
3.99%
Growth Rates
1Year -307.10%
3Years -2.55%
5Years -13.77%
7Years -3.70%
10Years -9.95%
-24.7 M NET INCOME
0.23%
Growth Rates
1Year -553.51%
3Years 2.15%
5Years -18.97%
7Years -0.32%
10Years -9.67%
-9.93 M OPERATING CASH FLOW
-327.14%
Growth Rates
1Year 78.82%
3Years 50.96%
5Years -3.67%
7Years 24.22%
10Years 9.22%
8.27 M INVESTING CASH FLOW
787.12%
Growth Rates
1Year -55.41%
3Years 129.15%
5Years 16.52%
7Years 12.72%
10Years 15.99%
-1.68 M FINANCING CASH FLOW
61.15%
Growth Rates
1Year -205.60%
3Years -6.97%
5Years -1.50%
7Years -33.52%
10Years -1.19%
Balance Sheet Innate Pharma S.A.
image
Current Assets 85.7 M
Cash & Short-Term Investments 80.8 M
Receivables 1.64 M
Other Current Assets 3.33 M
Non-Current Assets 25.3 M
Long-Term Investments 10.3 M
PP&E 5.13 M
Other Non-Current Assets 9.9 M
72.73 %3.00 %9.26 %4.62 %8.92 %Total Assets$111.1m
Current Liabilities 33 M
Accounts Payable 7.92 M
Short-Term Debt 8.71 M
Other Current Liabilities 16.4 M
Non-Current Liabilities 69.2 M
Long-Term Debt 22.3 M
Other Non-Current Liabilities 47 M
7.75 %8.52 %15.99 %21.80 %45.93 %Total Liabilities$102.2m
EFFICIENCY
Earnings Waterfall Innate Pharma S.A.
image
Revenue 12.6 M
Cost Of Revenue 0
Gross Profit 12.6 M
Operating Expenses 64.2 M
Operating Income -51.6 M
Other Expenses -2.1 M
Net Income -49.5 M
20m20m10m10m00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)13m013m(64m)(52m)2m(49m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
Averages
1Year 0.00%
3Years -4.01%
5Years -54.27%
7Years -31.98%
10Years -38.28%
-468.02% OPERATING MARGIN
-468.02%
Averages
1Year -468.02%
3Years -171.97%
5Years -181.84%
7Years -134.57%
10Years -111.12%
-391.94% NET MARGIN
-391.94%
Averages
1Year -391.94%
3Years -202.06%
5Years -237.22%
7Years -173.24%
10Years -137.59%
-560.01% ROE
-560.01%
Averages
1Year -560.01%
3Years -252.53%
5Years -170.73%
7Years -123.07%
10Years -91.24%
-44.54% ROA
-44.54%
Averages
1Year -44.54%
3Years -32.11%
5Years -27.85%
7Years -20.54%
10Years -16.05%
-59.12% ROIC
-59.12%
Averages
1Year -59.12%
3Years -26.40%
5Years -21.45%
7Years -16.39%
10Years -13.77%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Innate Pharma S.A.
image
250m250m200m200m150m150m100m100m50m50m00(50m)(50m)(100m)(100m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -49.5 M
Depreciation & Amortization 1.99 M
Capital Expenditures -391 K
Stock-Based Compensation 3.94 M
Change in Working Capital 39.2 M
Others 36.6 M
Free Cash Flow -7.29 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Innate Pharma S.A.
image
IPHA has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 5
6. Ownership
Insider Ownership Innate Pharma S.A.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences MARSEILLE, France--(BUSINESS WIRE)-- #InvestorRelations--Innate Pharma announces its participation in H.C. Wainwright and Wolfe Research Healthcare Conferences. businesswire.com - 3 weeks ago
Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the presentation of preclinical data for IPH6501, its proprietary ANKET® targeting CD20 currently under investigation in a Phase 1/2 study in relapsed and/or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) (NCT06088654), at the European Hematology Association (EHA) Congress 2025, taking place June 12-15 in Milan, Italy. R-CHOP is an establish. businesswire.com - 3 weeks ago
Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences MARSEILLE, France--(BUSINESS WIRE)-- #IRConferences--Innate Pharma announces its participation in upcoming investor conferences. businesswire.com - 1 month ago
Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the presentation of long-term follow-up data from the Phase 2 TELLOMAK clinical trial evaluating lacutamab, an anti-KIR3DL2 monoclonal antibody, in patients with Sézary syndrome (SS) and mycosis fungoides (MF), two rare and aggressive forms of cutaneous T-cell lymphoma (CTCL). The results will be presented at the American Society of Clinical Oncol. businesswire.com - 1 month ago
Outcome of Innate Pharma's 2025 Annual General Meeting MARSEILLE, France--(BUSINESS WIRE)-- #AG--Outcome of Innate Pharma's 2025 Annual General Meeting. businesswire.com - 1 month ago
Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that four abstracts with Innate's drugs in clinical development have been accepted for the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, taking place May 30-June 3, 2025 in Chicago, Illinois. “We are looking forward to participating in the ASCO Annual Meeting 2025, where four abstracts with Innate's drugs in clinical developmen. businesswire.com - 1 month ago
Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that an abstract regarding IPH6501, its ANKET® targeting CD20 B cells currently developed in relapsed and/or refractory Non-Hodgkin Lymphoma, has been selected for the European Hematology Association (EHA) Congress 2025, taking place June 12-15 in Milan, Italy. Abstract details Antitumor characterization of IPH6501, a novel il2v-armed tetraspecifi. businesswire.com - 1 month ago
Innate Pharma S.A. (IPHA) Q1 2025 Earnings Call Transcript Innate Pharma S.A. (NASDAQ:IPHA ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Corporate Participants Henry Wheeler - VP, IR and Communications Jonathan Dickinson - Chief Executive Officer Yannis Morel - Chief Operating Officer Sonia Quaratino - Chief Medical Officer Frederic Lombard - Chief Financial Officer Conference Call Participants Daina Graybosch - Leerink Partners Swayampakula Ramakanth - H.C. seekingalpha.com - 1 month ago
Innate Pharma Reports First Quarter 2025 Business Update and Financial Results MARSEILLE, France--(BUSINESS WIRE)-- #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the quarter ending March 31, 2025. “The first quarter of 2025 was marked by significant progress across both our pipeline and strategic partnerships,” said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “Sanofi's €15 million equity investment reflects our shared conviction in the potential of ou. businesswire.com - 1 month ago
Innate Pharma announces conference call and webcast for Q1 2025 business update MARSEILLE, France--(BUSINESS WIRE)-- #innatepharma--Innate Pharma announces conference call and webcast for Q1 2025 business update. businesswire.com - 2 months ago
Innate Pharma Files Its 2024 Universal Registration Document (Document d'enregistrement universel) and 2024 Annual Report on Form 20-F MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2024 Universal Registration Document (Document d'enregistrement universel) for the year ending December 31, 2024 with the French market authority “Autorité des Marchés Financiers” (“AMF”) on April 30, 2025. It can be downloaded (in French) on the Company's website and on the AMF's website. The Company also announced today the fil. businesswire.com - 2 months ago
Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting MARSEILLE, France--(BUSINESS WIRE)-- #AACR--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today shared new preclinical data for IPH4502, its novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4. The data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2025. Nectin-4 targeting is validated by enfortumab vedotin (EV), an ADC with a monomethyl auristatin E (MMAE) payload,. businesswire.com - 2 months ago
8. Profile Summary

Innate Pharma S.A. IPHA

image
COUNTRY FR
INDUSTRY Biotechnology
MARKET CAP $ 168 M
Dividend Yield 0.00%
Description Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.
Contact 117, Avenue de Luminy, Marseille, 13009 https://www.innate-pharma.com
IPO Date Oct. 17, 2019
Employees 181
Officers Dr. François Romagné Ph.D. Founder Mr. Frederic Lombard M.B.A. Senior Vice President & Chief Financial Officer Mr. Eric Vivier D.V.M., M.B.A., Ph.D. Founder, Senior Vice President & Chief Scientific Officer Dr. Marc Bonneville Ph.D. Founder Mr. Henry Wheeler M.Sc. Vice President of Investor Relations & Communication Dr. Sonia Quaratino M.D., Ph.D. Executive Vice President, Chief Medical Officer & Member of Executive Board Mr. Jonathan E. Dickinson B.Sc., M.B.A. Chairman of the Executive Board & Chief Executive Officer Mr. Jean Jacques Fournié Ph.D. Founder Mr. Alessandro Moretta M.D., Ph.D. Founder Mr. Yannis Morel Ph.D. Executive Vice President, Chief Operating Officer & Member of Executive Board